Registry for patients with Acute Myeloid Leukemia
Acute Myeloid Leukemia Registry - Prospective National Multicentric Observational Study
This study is creating a registry to track 250 patients with Acute Myeloid Leukemia over three years to better understand the disease and its treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Turkish Hematology Association Academic / other |
| Locations | 1 site (Antalya) |
| Trial ID | NCT05979675 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a disease registry for patients diagnosed with Acute Myeloid Leukemia (AML) after January 1, 2020. It will include 250 prospective patients from 20 hematology clinics across Turkey, who will be followed for 36 months. The study will collect data on patient demographics, treatment regimens, and outcomes to better understand AML. The total duration of the study is 60 months, allowing for comprehensive data collection and analysis.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with Acute Myeloid Leukemia after January 1, 2020.
Not a fit: Patients under 18 years old will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of AML and improve patient management and treatment strategies.
How similar studies have performed: While this approach is observational and builds on existing registries, similar studies have shown success in improving patient outcomes and treatment understanding in hematological malignancies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed as AML after 1 Jan 2020 * Patients signed informed consent form Exclusion Criteria: * Patients under 18 years old
Where this trial is running
Antalya
- Antalya Training and Research Hospital — Antalya, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Volkan Karakus, Assoc. Prof.
- Email: dr_v_karakus@yahoo.com
- Phone: 905057656778
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.